Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer
Authors
Keywords
Prostate cancer, Cancer treatment, Chemotherapy, Gene expression, Cancer detection and diagnosis, Polymerase chain reaction, Androgens, Specimen preparation and treatment
Journal
PLoS One
Volume 15, Issue 1, Pages e0226219
Publisher
Public Library of Science (PLoS)
Online
2020-01-28
DOI
10.1371/journal.pone.0226219
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients
- (2019) Carlo Cattrini et al. Cancers
- PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis
- (2018) Sara Bravaccini et al. Scientific Reports
- Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative to Tissue Biopsy
- (2018) José Marrugo-Ramírez et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns
- (2017) Bram De Laere et al. EUROPEAN UROLOGY
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- 225Ac-PSMA-617 for PSMA-Targeted -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Current use of PSMA–PET in prostate cancer management
- (2016) Tobias Maurer et al. Nature Reviews Urology
- Treatment of mCRPC in the AR-axis-targeted therapy-resistant state
- (2015) K. Chi et al. ANNALS OF ONCOLOGY
- Serial blood-based analysis of AR-V7 in men with advanced prostate cancer
- (2015) M. Nakazawa et al. ANNALS OF ONCOLOGY
- Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) C. Parker et al. ANNALS OF ONCOLOGY
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer
- (2015) Yohann Loriot et al. EUROPEAN JOURNAL OF CANCER
- Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells
- (2015) Wendy Onstenk et al. EUROPEAN UROLOGY
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy
- (2015) B. Meller et al. EJNMMI Research
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
- (2014) Cassandra L Hodgkinson et al. NATURE MEDICINE
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer
- (2013) R.J. van Soest et al. EUROPEAN JOURNAL OF CANCER
- Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
- (2012) J. Mezynski et al. ANNALS OF ONCOLOGY
- Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer
- (2012) David T. Miyamoto et al. Cancer Discovery
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of Mutations inEGFRin Circulating Lung-Cancer Cells
- (2008) Shyamala Maheswaran et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started